Latest Financial Results
Quarter Ended Sep 30, 2022
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2021
Inhibikase Therapeutics, Inc. is a pharmaceutical company focused on the development of protein kinase inhibitors for treatment of neurological infections and neurodegenerative diseases. The Company’s pipeline includes multiple product candidates developed from its proprietary RAMP drug innovation and prodrug technology engines, using the same clinically validated kinase target. The Company is headquartered in Atlanta with additional offices in Boston, Massachusetts.
Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway
Atlanta, GA 30339
American Stock Transfer & Trust Company, LLC